Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
28
8
2021
medline:
2
2
2022
entrez:
27
8
2021
Statut:
ppublish
Résumé
The objective of the review is to evaluate the measurement properties of rating scales that have been used to assess the components of medication adherence in patients with Parkinson's disease. Drug therapy is a central strategy in the control of Parkinson's disease symptoms. Measuring behaviors related to medication adherence in patients with Parkinson's disease is vital to understanding the therapeutic response. Consequently, it is necessary to define which instrument offers the most reliable and valid screening. This review will consider studies in English and Portuguese using structured rating scales to assess medication adherence in people with Parkinson's disease. Studies including data from patients with different diseases in addition to Parkinson's disease will be included only if data are clearly available for each disorder covered. Study protocols, letters to the editors, reviews, and studies with clinical judgment scales but no operationally defined anchor points will be excluded. A three-step search strategy will be utilized. Databases will include MEDLINE (PubMed), LILACS (BVS Portal), PsycINFO (APA PsycNet), CINAHL (EBSCO), Web of Science (Clarivate Analytics), Embase, and Scopus (Elsevier). The search strategy will be presented using a PRISMA flow diagram. Eligible studies will be critically appraised for methodological quality using the COSMIN Risk of Bias checklist. Criteria for good measurement properties of the selected scales will be summarized narratively using COSMIN, the Movement Disorder Society Rating Scale Program Committee methodology, the World Health Organization concepts, and the ABC taxonomy of medication adherence. The certainty of the evidence will be determined using the modified GRADE recommendations. PROSPERO (CRD42021211099).
Identifiants
pubmed: 34446669
doi: 10.11124/JBIES-21-00024
pii: 02174543-202201000-00018
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260-269Informations de copyright
Copyright © 2021 JBI.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Dorsey ER, Bloem BR. The Parkinson pandemic—a call to action. JAMA Neurol 2018;75 (1):9.
Lang AE, Shulman G. Perspectives of Parkinson's disease at 200 years: progress, new faces, and unmet needs. UTMJ 2016;93 (2):6–8.
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson's disease: a review. JAMA 2020;323 (6):548–560.
Malek N, Grosset DG. Medication adherence in patients with Parkinson's disease. CNS Drugs 2015;29 (1):47–53.
Fabbrini G, Abbruzzese G, Barone P, Antonini A, Tinazzi M, Castegnaro G, et al. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Int J Clin Pract 2012;18 (2):963–971.
Drey N, Mckeown E, Kelly D, Gould D. Adherence to antiparkinsonian medication: an in-depth qualitative study. Int J Nurs Stud 2012;49 (7):863–871.
Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24 (6):826–832.
Daley DJ, Deane KHO, Gray RJ, Clark AB, Pfeil M, Sabanathan K, et al. Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial. Int J Clin Pract 2014; (3):963–971.
Daley DJ, Myint PK, Gray RJ, Deane KHO. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord 2012;18 (10):1053–1061.
Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Reports 2019;92 (2):117–122.
Sabaté E. Adherence to long-term therapies: evidence for action [internet]. World Health Organization (WHO); 2003 [cited 2021 May 25]. Available from: https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf.
Vrijens B, De Geest S, Hughes DA, Kardas P, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012;73 (5):691–705.
Tosin MHS, Stebbins GT, Goetz CG, Santana RF, Leite MAA, Oliveira BGRB. Measuring medication adherence in Parkinson's disease: a systematic review of contributing components in rating scales. Mov Disord Clin Pract 2020;7 (6):607–615.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24 (1):67–74.
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008;10 (5):348–354.
Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med 2017;377 (8):733–744.
Franke G, Jagla M, Reimer J, Haferkamp L, Türk T, Witzke O. [Recording of drug compliance in successful kidney transplant recipiients with an extended version of the Morisky score - the Essen Compliance Score (ECS)]. Psychother Psychosom Med Psychol 2009;59 (2): German.
Svarstad BL, Chewning BA, Sleath BL, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999;37 (2):113–124.
Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42 (3):241–247.
Tan X, Patel I, Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). Inov Pharm 2014;5 (3):1–8.
Martinez-Martin P, Forjaz MJ. Sampaio C, Goetz CG, Schrag A. How to evaluate validation data. Rating scales in Parkinson's disease. New York: Oxford University Press; 2012. 16–41.
Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60 (1):34–42.
Cohen J. Statistical power analysis for the behavioral sciences. New York: Routledge; 1998.
Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, et al. Global scales for cognitive screening in Parkinson's disease: critique and recommendations. Mov Disord 2018;33 (2):208–218.
Stephenson M, Riitano D, Wilson S, Leonardi-Bee J, Mabire C, Cooper K, et al. Chapter 12: Systematic reviews of measurement properties. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis [internet]. Adelaide: JBI; 2020 [cited 2021 May 25]. Available from: https://synthesismanual.jbi.global.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009;6 (7):e100009721.
Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, et al. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res 2018;27 (5):1171–1179.
Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res 2018;27 (5):1147–1157.
Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, de Vet HC, et al. COSMIN methodology for systematic reviews of Patient-Reported Outcome Measures (PROMs) – user manual [internet]. COSMIN; 2018 [cited 2021 May 25]. Available from: http://www.cosmin.nl/.